Results of using revascularized flaps in patients with oral cancer after neoadjuvant chemotherapy
Authors:
- Sh. I. MusinSMSh. I. Musin
- K. V. MenshikovKMK. V. Menshikov
- A. V. SultanbaevASA. V. Sultanbaev
- N. A. SharafutdinovNSN. A. Sharafutdinov
- M. M. ZamilovMZM. M. Zamilov
- R. T. AyupovRAR. T. Ayupov
- A. F. NasretdinovANA. F. Nasretdinov
- А. О. ГузьАГА. О. Гузь
- D. M. FatkullinDFD. M. Fatkullin
- A. N. RudykARA. N. Rudyk
Open Access
- 9 July 2025
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (2) , 56-65
Abstract
Introduction. In Russia, cancer of the oral mucosa is diagnosed in more than 9500 patients every year. In 65–70 % of cases, the disease is diagnosed at stages III–IV. Despite the use of combination treatment, prognosis in patients with stage III and IVA oral mucosa cancer remains unfavorable. Neoadjuvant chemotherapy is considered a strategy to decrease the risk of distant metastasis, decrease tumor volume, and affect the status of surgical resection margins.Aim. To evaluate the results of using revascularized flaps in patients with resectable stage III and IVA cancer of the oral mucosa who received neoadjuvant chemotherapy.Materials and methods. Retrospective analysis of data of 41 patients who underwent surgery in 2020–2023 at the Republican Clinical Oncological Dispensary (Ufa) was performed. All patients underwent R0 resection with subsequent defect reconstruction using revascularized flaps. Two groups were compared: primary patients (n = 31) and patients who received neoadjuvant therapy per the DCF (docetaxel, cisplatin, 5‑fluorouracil) (n = 10) scheme.Results. Overall rate of complications in the groups of primary patients and patients receiving neoadjuvant therapy per the DCF scheme was 16.1 and 20 %, respectively (p = 0.398), however the rate of flap loss was significantly higher in patients who underwent neoadjuvant chemotherapy: 40 % versus 9.7 % (p = 0.047). Recurrence rate in the neoadjuvant chemotherapy group was 10 %, in the group without neoadjuvant therapy it was 38.7 % (p = 0.129).Conclusion. Neoadjuvant chemotherapy can be associated with higher risk of microvascular complications and flap loss but it decreases the recurrence rate. Therefore, further search for the optimal treatment strategy for patients with cancer of the oral mucosa is necessary.Keywords
This publication has 30 references indexed in Scilit:
- Prognostic impact of bridge or neoadjuvant induction chemotherapy in patients with resected oral cavity cancer: A nationwide cohort studyCancer Medicine, 2024
- Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinomaOral Oncology, 2024
- The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction: A systematic review and meta-analysisJournal of Plastic, Reconstructive & Aesthetic Surgery, 2023
- A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstructionThe Breast, 2021
- The impacts of intra-arterial chemotherapy on head and neck microvascular reconstructionJournal of the Formosan Medical Association, 2020
- Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 TrialClinical and Translational Oncology, 2020
- Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancerCancer, 2020
- Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancerOral Oncology, 2019
- Survival outcomes after treatment of cancer of the oral cavity (1985–2015)Oral Oncology, 2019
- Functional outcome in patients with advanced head and neck cancer: surgery and reconstruction with free flaps versus primary radiochemotherapyEuropean Archives of Oto-Rhino-Laryngology, 2011